Volatile substance misuse: Clinical considerations, neuropsychopharmacology and potential role of pharmacotherapy in management

CNS Drugs

Volumn 26, Issue 11, 2012, Pages 927-935

  Garland, Eric L ^a   Howard, Matthew O ^b  

^a FLORIDA STATE UNIVERSITY   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINO 2 OXABICYCLO[3.1.0]HEXANE 4,6 DICARBOXYLIC ACID; ARIPIPRAZOLE; BACLOFEN; BUSPIRONE; LAMOTRIGINE; N METHYL DEXTRO ASPARTIC ACID; RISPERIDONE; VOLATILE AGENT;

ANTISOCIAL BEHAVIOR; ANXIETY DISORDER; DRUG DEPENDENCE; DRUG MISUSE; DRUG WITHDRAWAL; DSM-IV; EUPHORIA; GABAERGIC TRANSMISSION; HUMAN; INHALANT ABUSE; MOOD DISORDER; PERSONALITY DISORDER; PREVALENCE; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; PSYCHOPHARMACOTHERAPY; REVIEW; SUBSTANCE ABUSE; TOXIC INHALATION; VERTIGO; VIOLENCE; VISUAL HALLUCINATION; VOLATILE SUBSTANCE MISUSE;

ANIMALS; HUMANS; INHALANT ABUSE; INHALATION EXPOSURE; NEUROPSYCHOLOGY; PREVALENCE; PSYCHOPHARMACOLOGY; PSYCHOTROPIC DRUGS; VOLATILE ORGANIC COMPOUNDS; VOLATILIZATION;

EID: 84873443103     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.1007/s40263-012-0001-6     Document Type: Review

References (89)

1. Dell CA, Gust SW, MacLean S. Global issues in volatile substance misuse. Subst Use Misuse. 2011;46(Suppl. 1):1-7.
2. Neumark Y, Bar-Hamburger R. Volatile substance misuse among youth in Israel: results of a national school survey. Subst Use Misuse. 2011;46(Suppl. 1):21-6.
3. Haynes-Dowell M, Mateu-Gelabert P, Barros H, et al. Volatile substance misuse among high school students in South America. Subst Use Misuse. 2011;46(Suppl. 1):27-34.
4. Elkoussi A, Bakheet S. Volatile substance misuse among street children in upper Egypt. Subst Use Misuse. 2011;46(Suppl. 1):35-9.
5. Villatoro JA, Cruz S, Ortiz A, et al. Volatile substance misuse in Mexico: correlates and trends. Subst Use Misuse. 2011;46(Suppl. 1):40-5.
6. Sharma S, Lal R. Volatile substance misuse among street children in India: a preliminary report. Subst Use Misuse. 2011;46(Suppl. 1):46-9.
7. Vazan P, Khan MR, Poduska O, et al. Chronic toluene use among Roma youth in Eastern Slovakia. Subst Use Misuse. 2011;46(Suppl. 1):57-61.
8. Garland EL, Howard MO, Vaughn MG, et al. Volatile substance misuse in the United States. Subst Use Misuse. 2011;46(Suppl. 1):21-6.
9. Ives R. Meeting professionals' need in the United Kingdom for effective VSM interventions. Subst Use Misuse. 2011;46(Suppl. 1):134-9.
10. Balster RL. Inhalant abuse: a forgotten drug problem. College on Problems of Drug Dependence Presidential Address, Conference Proceedings. NIDA Res Monogr. 1996;174:3-8.
11. Dell CA, Dell DE, Hopkins C. Resiliency and holistic inhalant abuse treatment. J Aborig Health. 2005;2(1):4-13.
12. MacLean S, Cameron J, Harney A, Lee NK. Psychosocial therapeutic interventions for volatile substance use: a systematic review. Addiction. 2012;107(2):278-88.
13. Howard MO, Bowen SE, Garland EL, et al. Inhalant use and inhalant use disorders in the United States. Addict Sci Clin Pract. 2011;6(1):18-31.
14. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association; 2000.
15. Hall MT, Howard MO. Nitrite inhalation abuse in antisocial youth: prevalence, patterns, and predictors. J Psychoact Drugs. 2009;41(2):135-43.
16. Wu LT, Schlenger WE, Ringwalt CL. Use of nitrite inhalants ("poppers") among American youth. J Adolesc Health. 2005;37(1):52-60.
17. Garland EL, Howard MO, Perron BE. Nitrous oxide inhalation among adolescents: prevalence, correlates, and co-occurrence with volatile solvent inhalation. J Psychoact Drugs. 2009;41(4):337-47.
18. Howard MO, Balster RL, Cottler LB, et al. Inhalant use among incarcerated adolescents in the United States: prevalence, characteristics, and correlates of use. Drug Alcohol Depend. 2008;93(3):197-209.
19. Garland EL, Carter K, Howard MO. Prevalence, correlates, and characteristics of gasoline inhalation among high-risk youth: associations with suicidal ideation, self-medication, and antisociality. Bull Clin Psychopharmacol. 2011;21:104-12.
20. Garland EL, Howard MO. Inhalation of computer duster spray among adolescents: an emerging public health threat. Am J Drug Alcohol Abuse. 2010;36(6):320-4.
21. Sharp CW, Howard MO, Schiffer WK. Chapter 20: Inhalants. In: Lowinson JH, Ruiz P, Millman RB, Langrod JG, editors. Substance abuse: a comprehensive textbook. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2011. p. 284-318.
22. Balster RL, Cruz SL, Howard MO, et al. Classification of abuse inhalants. Addiction. 2009;104(6):878-82.
23. Garland EL, Howard MO. Phenomenology of adolescent inhalant intoxication. Exp Clin Psychopharmacol. 2010;18(6):498-509.
24. MacLean S. Volatile bodies: stories of corporeal pleasure and damage in marginalized young people's drug use. Int J Drug Policy. 2008;19(5):375-83.
25. Garland EL, Howard MO. Adverse consequences of acute inhalant intoxication. Exp Clin Psychopharmacol. 2011;19(2):134-44.
26. Howard MO, Jenson JM. Inhalant use among antisocial youth: prevalence and correlates. Addict Behav. 1999;24(1):59-74.
27. Sakai JT, Hall SK, Mikulich-Gilberts S, et al. Inhalant use, abuse, and dependence among adolescent patients: commonly comorbid problems. J Am Acad Child Adolesc Psychiatry. 2004;43(9):1080-8.
28. Compton W, et al. Inhalant use: characteristics and predictors. Am J Addict. 1994;3(3):263-72.
29. Perron BE, Howard MO, Maitra S. et al. Prevalence, timing, and predictors of transitions from inhalant use to Inhalant Use Disorders. Drug Alcohol Depend. 2009;100(3):277-84.
30. Ridenour TA, Bray B, Cottler LC. Reliability of use, abuse, and dependence of four types of inhalants in adolescents and young adults. Drug Alcohol Depend. 2007;91(1):40-9.
31. Perron BE, Howard MO. Adolescent inhalant use, abuse, and dependence. Addiction. 2009;104(7):1185-92.
32. Howard MO, Perron BE. A survey of inhalant use disorders among delinquent youth: prevalence, clinical features, and latent structure of DSM-IV diagnostic criteria. BMC Psychiatry. 2009; 9(8).
33. Cairney S, Dingwall K. The mysterious practice of petrol sniffing in isolated indigenous groups. J Paediatr Child Health. 2010;46(9):510-5.
34. Driscoll DL, Dotterrer B, Collins D, Ogilvie K, Grube J, Johnson K. Demographic and contextual factors associated with inhalant use among youth in rural Alaska. Int J Circumpolar Health. 2012;71:1-4.
35. Howard MO, Perron BE, Vaughn MG, et al. Inhalant use, inhalant use disorders, and antisocial behavior: findings from the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). J Stud Alcohol Drug. 2010;71(2):201-9.
36. Wu LT, Howard MO. Psychiatric disorders in inhalant users: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Drug Alcohol Depend. 2007;88(2-3):146-55.
37. Wu LT, Howard MO. Substance use disorders among inhalant users: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Addict Behav. 2008;33(7):968-73.
38. Wu LT, Ringwalt CL. Inhalant use and disorders among adults in the United States. Drug Alcohol Depend. 2006;85:1-11.
39. Wu LT, Pilowsky DJ, Schlenger WE. Inhalant abuse and dependence among adolescents in the United States. J Am Acad Child Adolesc Psychiatry. 2004;43(10):1206-14.
40. Perron BE, Vaughn MG, Howard MO. Reasons for using inhalants: evidence for discrete classes in a sample of incarcerated adolescents. J Subst Abuse Treat. 2008;34:450-5.
41. Vaughn MG, Perron BE, Howard MO. Variations in social contexts and their effect on adolescent inhalant use: a latent profile investigation. Drug Alcohol Depend. 2007;91(2-3):129-33.
42. Howard MO, Perron BE, Sacco P, et al. Suicide ideation and attempts among inhalant users: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Suicide Life Threat Behav. 2010;40(3):276-86.
43. Freedenthal S, Vaughn MG, Jenson JM, et al. Inhalant use and suicidality among incarcerated youth. Drug Alcohol Depend. 2007;90(1):81-8.
44. Hall MT, Edwards JD, Howard MO. Accidental deaths due to inhalant misuse in North Carolina: 2000-2008. Subst Use Misuse. 2010;45:1330-9.
45. Perron BE, Howard MO, Vaughn MG, et al. Inhalant withdrawal as a clinically significant feature of inhalant dependence disorder. Med Hypotheses. 2009;73(6):935-7.
46. Perron BE, Mowbray O, Bier S, et al. Service use and treatment barriers among inhalant users. J Psychoactive Drugs. 2011;43(1):69-75.
47. Beauvais F, Jumper-Thurman P, Plested B, et al. A survey of attitudes among drug user treatment providers toward the treatment of inhalant users. Subst Use Misuse. 2002;37(11):1391-410.
48. Gerasimov MR. Brain uptake and biodistribution of toluene in nonhuman primates and mice. Methods Enzymol. 2004;385:334-49.
49. Gerasimov MR, Ferrieri RA, Pareto D, Logan J, Alexoff D, Ding YS. Synthesis and evaluation of inhaled butane and intravenously injected acetone as potential radiotracers for studying inhalant abuse. Nucl Med Biol. 2005;32(2):201-8.
50. Bowen SE, Batis JC, Paez-Martinez N, Cruz SL. The last decade of solvent research in animal models of abuse: mechanistic and behavioral studies. Neurotoxicol Teratol. 2006;28(6):636-47.
51. Balster RL. Neural basis of inhalant abuse. Drug Alcohol Depend. 1998;51(1-2):207-14.
52. Pogorelov VM, Kovalev GI. Dopaminergic involvement in the process of reinforcement from diethyl ether vapour in rats. Prog Neuropsychopharmacol Biol Psychiatry. 1999;23:1132-56.
53. Bowen SE, Charlesworth JD, Tokarz ME, Wright JW, Wiley JL. Decreased sensitivity in adolescent vs. adult rats to the locomotor activating effects of toluene. Neurotoxicol Teratol. 2007;29:599-606.
54. Saracibar G, Hernandez ML, Echevarria E, Barbero I, Gutierrez A, Casis O, et al. Toluene alters mu-opioid receptor expression in the rat brainstem. Ind Health. 2001;39(3):231-4.
55. Williams JM, Stafford D, Steketee JD. Effects of repeated inhalation of toluene on ionotropic GABAA and glutamate receptor subunit levels in rat brain. Neurochem Int. 2005;46(1):1-10.
56. Cruz SL, Mirshahi T, Thomas B, Balster RL, Woodward JJ. Effects of the abused solvent toluene on recombinant N-methyl-d-aspartate and non-N-methyl-d-aspartate receptors expressed in xenopus oocytes. J Pharmacol Exp Ther. 1998;286(1):334-40.
57. Bale AS, Tu Y, Carpenter-Hyland EP, Chandler LJ, Woodward JJ. Alterations in glutamatergic and gabaergic ion channel activity in hippocampal neurons following exposure to the abused inhalant toluene. Neuroscience. 2005;130(1):197-206.
58. Lubman DI, Yucel M, Lawrence AJ. Inhalant abuse among adolescents: neurobiological considerations. Br J Pharmacol. 2008;154:316-26.
59. Gmaz JM, Matthews BA, McKay BE. Toluene inhalation modulates dentate gyrus granule cell output in vivo. Neurotoxicol Teratol. 2012;34(4):403-12.
60. Beckley JT, Woodward JJ. The abused inhalant toluene differentially modulates excitatory and inhibitory synaptic transmission in deep-layer neurons of the medial prefrontal cortex. Neuropsychopharmacology. 2011;36(7):1531-42.
61. Beckstead MJ, Phelan R, Trudell JR, Bianchini MJ, Mihic SJ. Anesthetic and ethanol effects on spontaneously opening glycine receptor channels. J Neurochem. 2002;82(6):1343-51.
62. MacIver MB. Abused inhalants enhance GABA-mediated synaptic inhibition. Neuropsychopharmacology. 2009;34(10):2296-304.
63. Riegel AC, French ED. Abused inhalants and central reward pathways. Ann N Y Acad Sci. 2002;965(1):281-91.
64. Riegel AC, Zapata A, Shippenberg TS, French ED. The abused inhalant toluene increases dopamine release in the nucleus accumbens by directly stimulating ventral tegmental area neurons. Neuropsychopharmacology. 2007;32:1558-69.
65. 22 agonist binding in the rat caudate-putamen. Toxicology. 1995;100(1-3):185-94.
66. Cintra A, Aguirre JA, Andbjer B, Finnman UB, Hagman M, Agnati LF, et al. Subchronic toluene exposure in low concentrations produces signs of reduced dysfunction in the 6-hydroxydopamine lesioned nigrostriatal dopaminergic system of the rat. Neurosci Lett. 1999;274(1):5-8.
67. von Euler M, Pham TM, Hillefors M, Bjelke B, Henriksson B, von Euler G. Inhalation of low concentrations of toluene induces persistent effects on a learning retention task, beam-walk performance, and cerebrocortical size in the rat. Exp Neurol. 2000;163(1):1-8.
68. Páez-Martínez N, Ambrosio E, García-Lecumberri C, Rocha L, Montoya GL, Cruz SL. Toluene and TCE decrease binding to mu-opioid receptors, but not to benzodiazepine and NMDA receptors in mouse brain. Ann N Y Acad Sci. 2008;1139(1):390-401.
69. Feldman RS, Meyer JS, Quenzer LF. Principles of neuropsychopharmacology. Stamford: Sinauer Associates; 1997.
70. Lopreato GF, Phelan R, Borghese CM, Beckstead MJ, Mihic SJ. Inhaled drugs of abuse enhance serotonin-3 receptor function. Drug Alcohol Depend. 2003;70(1):11-5.
71. Bale AS, Smothers CT, Woodward JJ. Inhibition of neuronal nicotinic acetylcholine receptors by the abused solvent, toluene. Br J Pharmacol. 2002;137(3):375-83.
72. Del Re AM, Dopico AM, Woodward JJ. Effects of the abused inhalant toluene on ethanol-sensitive potassium channels expressed in oocytes. Brain Res. 2006;1087(1):75-82.
73. von Euler G, Fuxe K, Bondy SC. Ganglioside GM1 prevents and reverses toluene-induced increases in membrane fluidity and calcium levels in rat brain synaptosomes. Brain Res. 1990;508(2):210-4.
74. Shen Y-C. Treatment of inhalant dependence with lamotrigine. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31(3):769-71.
75. Erdoǧan A, Yurteri N. Aripiprazole treatment in the adolescent patients with inhalants use disorders and conduct disorder: a retrospective case analysis. In: Yeni symposium. 2010. p. 229-33.
76. Muralidharan K, Rajkumar RP, Mulla U, Nayak RB, Benegal V. Baclofen in the management of inhalant withdrawal: a case series. Prim Care Companion J Clin Psychiatry. 2008;10(1):48.
77. Garbutt JC, Kampov-Polevoy AB, Gallop R, Kalka-Juhl L, Flannery BA. Efficacy and safety of baclofen for alcohol dependence: a randomized, double-blind, placebo-controlled trial. Alcohol Clin Exp Res. 2010;34(11):1849-57.
78. Westermeyer J. The psychiatrist and solvent-inhalant abuse: recognition, assessment, and treatment. Am J Psychiatry. 1987;144(7):903-7.
79. Hernandez-Avila CA, Ortega-Soto HA, Jasso A, Hasfura-Buenaga CA, Kranzler HR. Treatment of inhalant-induced psychotic disorder with carbamazepine versus haloperidol. Psychiatr Serv. 1998;49(6):812-5.
80. Misra LK, Kofoed L, Fuller W. Treatment of inhalant abuse with risperidone. J Clin Psychiatry. 1999;60(9):620.
81. Lee DE, Schiffer WK, Dewey SL. Gamma-vinyl GABA (vigabatrin) blocks the expression of toluene-induced conditioned place preference (CPP). Synapse. 2004;54(3):183-5.
82. Riegel AC, Ali SF, French ED. Toluene-induced locomotor activity is blocked by 6-hydroxydopamine lesions of the nucleus accumbens and the mGluR2/3 agonist LY379268. Neuropsychopharmacology. 2003;28(8):1440-7.
83. Garland EL, Boettiger CA, Howard MO. Targeting cognitive-affective risk mechanisms in stress-precipitated alcohol dependence: an integrated, biopsychosocial model of allostasis, automaticity, and addiction. Med Hypotheses. 2011;76:745-54.
84. Koob GF, Volkow ND. Neurocircuitry of addiction. Neuropsychopharmacology. 2009;35(1):217-38.
85. George O, Koob GF. Individual differences in prefrontal cortex function and the transition from drug use to drug dependence. Neurosci Biobehav Rev. 2010;35:232-47.
86. Sofuoglu M. Cognitive enhancement as a pharmacotherapy target for stimulant addiction. Addiction. 2010;105(1):38-48.
87. Goldstein RZ, Woicik PA, Maloney T, Tomasi D, Alia-Klein N, Shan J, et al. Oral methylphenidate normalizes cingulate activity in cocaine addiction during a salient cognitive task. Proc Natl Acad Sci USA. 2010;107(38):16667-72.
88. Levin ED, McClernon FJ, Rezvani AH. Nicotinic effects on cognitive function: behavioral characterization, pharmacological specification, and anatomic localization. Psychopharmacology. 2006;184(3):523-39.
89. Niederhofer H. Treating inhalant abuse with buspirone. Am J Addict. 2007;16(1):69.